We then critically assess studies of B cell depleting therapies, including CD20 and CD19 targeting monoclonal antibodies, as well as the new class of B cell modulating substances, Bruton ́s tyrosinekinase (BTK) inhibitors, in MS, NMOSD and MOGAD. Here, BTK is linked to myeloid sarcoma.